Health Care • Biotechnology: Pharmaceutical Preparations
$2.11 ▲ +0.13
(+6.57%)
MKT CAP: $3.4M • VOL: 7.3K
52W L $2 52W H $47
ROARABLE / RQD
D • 46/100
PIOTROSKI
3 / 9
ERNA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $582.0K | $68.0K |
| YoY Revenue Growth % | — | +755.9% | — |
| Gross Profit | — | $486.0K | — |
| Gross Margin % | — | 83.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.3M | -$15.7M | -$21.1M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$14.1M | -$44.5M | -$21.7M |
| EBITDA (Normalized) | -$9.3M | -$15.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.0M | -$15.8M | -$20.4M |
| Capital Expenditures (CapEx) | $37.0K | $369.0K | — |
| Free Cash Flow (FCF) | -$7.1M | -$16.2M | -$20.4M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | — | $1.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $2.4M | $1.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ERNA.